Literature DB >> 20660883

Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report.

Michael R Langlois1, Francis Derk, Ronald Belczyk, Thomas Zgonis.   

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis are rare; however, when they occur, they usually present with severe reactions in response to medications and other stimuli. These reactions are characterized by mucocutaneous lesions, which ultimately lead to epidermal death and sloughing. We present a unique case report of Stevens-Johnson syndrome and associated toxic epidermal necrolysis in a 61-year-old man after treatment for a peripherally inserted central catheter infection with trimethoprim-sulfamethoxazole. This case report reviews a rare adverse reaction to a commonly prescribed antibiotic drug used in podiatric medical practice for the management of diabetic foot infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660883     DOI: 10.7547/1000299

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  4 in total

Review 1.  [Allergies to antibiotic drugs: their importance in otorhinolaryngology].

Authors:  L Klimek; C Aderhold; A Sperl
Journal:  HNO       Date:  2013-05       Impact factor: 1.284

Review 2.  Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.

Authors:  Alison E Barnhill; Matt T Brewer; Steve A Carlson
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole.

Authors:  Jharendra P Rijal; Tiffany Pompa; Smith Giri; Vijaya Raj Bhatt
Journal:  BMJ Case Rep       Date:  2014-07-09

4.  Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim/sulfamethoxazole and dapsone.

Authors:  Pradeep Reddy Kathi; Maher Tama; Murray Ehrinpreis; Milton Mutchnick; Maria Westerhoff; Jonathan Mowers; Robert John Fontana
Journal:  Clin J Gastroenterol       Date:  2019-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.